Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and Evergreen Theragnostics, Inc., a radiopharmaceutical contract manufacturer, have recently announced that the companies have entered into an agreement whereby Evergreen will provide US-based manufacturing for Precirix's lead product candidate, CAM-H2.
CAM-H2 is a novel precision therapy that leverages the favorable characteristics of single-domain antibodies to effectively irradiate cancer lesions while sparing healthy tissue and is being evaluated in a Phase I/II clinical trial targeting HER2-positive metastatic breast and gastric cancer. Evergreen will manufacture CAM-H2, an I-131 based radiopharmaceutical, at its new state-of-the-art facility in Springfield, New Jersey, USA. This facility is opening in 2021, and is located near Newark Liberty International Airport within driving distance of John F. Kennedy International Airport. The location is ideal for receiving isotope shipments from Europe and distributing the finished product to hospitals across North America.
To read more please visit:
Source: Evergreen Theragnostics, Inc.